Insight Molecular Diagnostics Inc. Common Stock IMDX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$23K+20.7% | -$26K+13.3% | -$29K+6.5% | -$25K-213% | -$29K-93.3% | ||
| $32K-98.5% | $1.14M-23.4% | $260K+126% | $518K+398% | $2.14M+1,115% | ||
| $17K-97.9% | $643K-26.0% | $121K+181% | $168K+425% | $813K+646% | ||
| $15K-98.9% | $496K-19.6% | $139K+93.1% | $350K+386% | $1.33M+1,878% | ||
| 46.9%-15.1pp | 43.5%+2.0pp | 53.5%-9.1pp | 67.6%-1.7pp | 62%+23.9pp | ||
| $4.95M+69.4% | $5.83M+158% | $3.88M+37.7% | $3.28M+33.8% | $2.92M+26.5% | ||
| $2.4M+99.2% | $2.29M+90.6% | $1.39M+32.9% | $1.46M+71.2% | $1.21M+42.6% | ||
| $2.99M-4.0% | $2.33M-9.1% | $2.55M-0.8% | $2.65M+10.0% | $3.12M+16.5% | ||
| $4.43M-45.5% | $23.93M-30.1% | $11.19M-17.5% | $10.19M+118% | $8.12M-12.8% | ||
| -$4.41M+35.1% | -$23.44M+30.3% | -$11.05M+18.3% | -$9.84M-112% | -$6.8M+26.6% | ||
| -13,790.6%-13,473pp | -2,057.5%+205pp | -4,249.2%+7,503pp | -1,900%+2,554pp | -318%+4,947pp | ||
| $123K-3.9% | $480K+314% | $194K+782% | $100K-2.0% | $128K-7.2% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$4.29M+35.7% | -$22.96M+31.5% | -$10.85M+19.6% | -$9.74M-115% | -$6.67M+26.9% | ||
| -13,406.3%-13,094pp | -2,015.4%+240pp | -4,174.6%+7,558pp | -1,880.7%+2,475pp | -312%+4,875pp | ||
| -$0.12+53.8% | -$0.74+67.8% | -$0.34+65.3% | -$0.30+16.7% | -$0.26+77.0% | ||
| -$3.78M+40.1% | -$22.87M+30.9% | -$10.46M+20.7% | -$9.28M-114% | -$6.32M+29.5% | ||
| -11,818.8%-11,523pp | -2,008.1%+218pp | -4,024.6%+7,451pp | -1,792.1%+2,369pp | -295.4%+4,792pp | ||
| -$4.41M+35.1% | -$23.44M+30.3% | -$11.05M+18.3% | -$9.84M-112% | -$6.8M+26.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Insight Molecular Diagnostics Inc. Common Stock's revenue?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) generated $1.9M in revenue over the trailing twelve months, down 49.3% year over year.
- Is Insight Molecular Diagnostics Inc. Common Stock profitable?
- Insight Molecular Diagnostics Inc. Common Stock is not currently profitable: it reported a net loss of $47.8M over the trailing twelve months, a -2454.6% net margin.
- What are Insight Molecular Diagnostics Inc. Common Stock's profit margins?
- Gross margin is 51.3% and operating margin is -2500.7%, with a -2454.6% net margin.
- What is Insight Molecular Diagnostics Inc. Common Stock's earnings per share?
- Insight Molecular Diagnostics Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.50.
- Where does Insight Molecular Diagnostics Inc. Common Stock's income statement data come from?
- Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
